Searching…
TREMFYA ® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis. If your healthcare provider decides that you or a caregiver may be able to give your injections at home,...
May 28, 2025 · Tremfya is a biologic medicine used to treat moderate to severe ulcerative colitis. Ulcerative colitis is an inflammatory bowel disease. It causes irritation, inflammation, and ulcers in parts of ...
Sep 11, 2024 · TREMFYA ® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson ’s leadership in inflammatory bowel disease The first ...
3 days ago · TREMFYA ® is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with active psoriatic arthritis. TREMFYA ® is indicated for the treatment o...
Oct 9, 2025 · SUMMARY A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, treat-through study (ASTRO) evaluated the efficacy and safety of TREMFYA subcutaneous (SC) induction in adult...
Aug 18, 2025 · Tremfya is a brand-name medication used to treat moderate to severe ulcerative colitis in adults by targeting a protein that reduces inflammation in the large intestine. Treatment with Tremfya ...
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
TREMFYA ® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis. TREMFYA ® is a prescription medicine used to treat adults with moderately to severely active Crohn’s disease.
Oct 24, 2025 · TREMFYA® (guselkumab) receives European Commission approval for subcutaneous induction through to maintenance in adults with ulcerative colitis, now the first IL-23 inhibitor with a fully ...
Sep 23, 2024 · The FDA has approved Tremfya® (guselkumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC).
